Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"
- PMID: 37599049
- DOI: 10.1016/j.jtho.2023.05.022
Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"
Comment on
-
First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.J Thorac Oncol. 2023 Sep;18(9):e101-e102. doi: 10.1016/j.jtho.2022.11.024. J Thorac Oncol. 2023. PMID: 37599048 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical